A new vaccine has been developed against the COVID-19 virus. According to the news of The Guardian, scientists from the Texas Children’s Hospital Vaccine Development Center, Dr. Peter Hotez and Dr. Maria Bottazzi announced that they have developed a new COVID-19 vaccine, injured by yeast. The team, which has been working on Sars and Mers viruses and developing a vaccine prototype since 2011, named the vaccine they developed based on these prototypes, ‘Corbevax’.
Stating that they will not obtain a patent for the new COVID-19 vaccine they have developed, Dr. Bottasia; He stated that more than 60 vaccines have been developed based on the same technology. Regarding his decision not to patent, Bottazzi noted, “We want to do the world a favor. It was the right thing to do, and morally we should have done it. We decided without blinking.”
Corbevax will be more affordable than other COVID-19 vaccines
Bottazzi for the Corvebax vaccine, which is based on the principle that a real COVID-19 spike protein is placed in the yeast cell and the basic protein is copied and then added to the immune system, said, “We make the protein directly and synthetically, using a yeast system in the laboratory. We enable the yeast to develop the same protein as in the virus. In this way, the body We are immunizing.”
Similar to the Hepatitis B vaccine, clinical test results for Corbevax, developed with yeast, have not yet been released due to resource constraints; However, in the statement made by the hospital, it was reported that the vaccine was 90 percent effective against the original Covid virus and 80 percent effective against the Delta variant. Tests are ongoing to understand how Corbevax affects the Omicron variant.
Bottazzi noted that they could not get any help from government institutions for financing; He appealed to the benefactors to continue the work. In addition, it was stated that the Corbevax vaccine will be much more affordable than the current COVID-19 vaccines on the market.
50315
